Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis

por Norum, Jan, Antonsen, Margareth Aarag, Tollåli, Terje, Al-Shibli, Khalid, Andersen, Gry, Svanqvist, Kristin Helene, Helbekkmo, Nina
Publicado 2017